Clinical Trials Logo

Neuromuscular Blockade clinical trials

View clinical trials related to Neuromuscular Blockade.

Filter by:

NCT ID: NCT05992090 Recruiting - Clinical trials for Neuromuscular Blockade

Neuromuscular Blockade Monitoring Using Kine-myography vs Electromyography.

Start date: October 10, 2023
Phase:
Study type: Observational

This study aims to compare two monitoring methods of neuromuscular blockade - Kine-myography and Electromyography. The main questions to answer are: - are electromyography and kine-myography interchangeable - is electromyography linked to fewer fault results - is electromyography using lower energy to stimulate nerves The type of study is a multicentric observational clinical trial. Subjects are patients undergoing general anaesthesia with the use of rocuronium or cis-atracurium. In each patient, the neuromuscular blockade will be monitored using kine-myograph and electromyography simultaneously.

NCT ID: NCT05820802 Recruiting - Clinical trials for Neuromuscular Blockade

High Dimensional Analysis of Immune Cells in Pediatric Patients

Start date: April 27, 2023
Phase:
Study type: Observational

The purpose of this study is to characterize immune cells using single-cell transcriptomic analysis in pediatric patients aged 2 to 18 years undergoing general anesthesia who are expected to receive Rocuronium, a non-depolarizing neuromuscular blocking agent, in the event of an allergic reaction.

NCT ID: NCT05794503 Recruiting - Clinical trials for Neuromuscular Blockade

Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex

Start date: September 11, 2023
Phase: Early Phase 1
Study type: Interventional

This study is intended to be a single-site, prospective, randomized, controlled study that intends to enroll a total of 230 patients undergoing laparoscopic cholecystectomy at Parkland Hospital. Patients will be randomized to receive either neostigmine or sugammadex for reversal of rocuronium-induced neuromuscular blockade. A standardized anesthetic protocol that is usual and customary for the type of operation the patient is having will be provided to the anesthesia teams of enrolled subjects. The remainder of the anesthetic care of the subject will not deviate from the standard of care. To account for protocol deviations and patient dropout, up to 250 randomization envelopes will be made and enrollment will continue until there are 230 completed enrollments.

NCT ID: NCT05788718 Recruiting - Anesthesia Clinical Trials

An Observational Study to Analyze the Prescription Pattern of Sugammadex and Its Effectiveness and Safety

SECURE
Start date: April 11, 2023
Phase:
Study type: Observational

The purpose of this observational study is to evaluate patients who are planning to administer sugammadex after rocuronium or vecuronium is used. The main questions it aims to answer are: 1. Prescription pattern of sugammadex 2. Effectiveness and safety of sugammadex Since this study is observational, only data generated under daily treatment are to be collected, and no additional tests or drug administration is conducted for the study. The patients are observed from baseline to 24 hours after the initial administration of sugammadex.

NCT ID: NCT05784610 Enrolling by invitation - Clinical trials for Neuromuscular Blockade

Interest of the Automated Management of Deep Neuromuscular Blockade Monitoring (CURATP)

CURATP
Start date: November 1, 2022
Phase: N/A
Study type: Interventional

Neuromuscular blockade (NMB) recommendations updated in 2018 by the Société Française d'Anesthésie et Réanimation (SFAR) recommend the use of NMB agents to facilitate surgical procedure during abdominal surgery by laparotomy or laparoscopy. This study aims to evaluate deep NMB monitoring with automated management of NMB depth measurement (ATP mode) versus non-automated monitoring (PTC/TOF), in order to improve the maintenance of deep NMB during abdominal surgery.

NCT ID: NCT05718934 Completed - Clinical trials for Neuromuscular Blockade

Low Dose of Sugammadex vs Neostigmine and Glycopyrrolate for the Reversal of Rocuronium

SUGANEO
Start date: November 8, 2022
Phase: Phase 4
Study type: Interventional

The aim of this study is to compare the use of a low dose sugammadex and neostigmine combined to glycopyrrolate to reverse a rocuronium induced moderate neuromuscular blockade.

NCT ID: NCT05689957 Completed - Clinical trials for Neuromuscular Blockade

Moderate vs Deep Neuromuscular Block in Lower Pressure Pneumoperitoneum

Start date: December 13, 2020
Phase: N/A
Study type: Interventional

The investigators hypothesized that deep neuromuscular block compare to moderate neuromuscular block would reduce the rate of increasing intraabdominal pressure and operation can be completely done in lower pressure pneumoperitoneum and would improve laparoscopic space by measuring distance from the sacral promontory to the inserted trocar in patients undergoing laparoscopic gynaecological surgery.

NCT ID: NCT05687253 Completed - Surgery Clinical Trials

Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery

Start date: October 25, 2022
Phase: Phase 2
Study type: Interventional

Assessment of Intubation conditions following administration of neuromuscular blocking agents; BX1000 (investigational) or rocuronium (active control).

NCT ID: NCT05661409 Recruiting - Clinical trials for Neuromuscular Blockade

Sugammadex as Rescue Therapy

Start date: July 21, 2023
Phase: Phase 4
Study type: Interventional

Neuromuscular blocking agents (NMBAs) are commonly used in the practice of anesthesiology for skeletal muscle relaxation to facilitate tracheal intubation, mechanical ventilation, and to provide optimal surgical conditions. In order to prevent residual NMB, it is vital to adequately reverse any use of a non-depolarizing NMBA. This was historically done using an anticholinesterase such as neostigmine, which would increase the concentration of acetylcholine at the neuromuscular junction leading to the return of neuromuscular transmission. Unfortunately, there are disadvantages to the use of an anticholinesterase. It was in this context that sugammadex was found to be a valuable addition to the anesthesiologist's armamentarium. It is a modified γ-cyclodextrin that encapsulates the aminosteroid NMBAs rocuronium and vecuronium. This project is a double-blind randomized placebo-controlled dose-response trial that aims to determine the time taken to achieve adequate reversal comparing five doses of sugammadex as rescue therapy following inadequate reversal with neostigmine. The study team will recruit patients aged 18 years and above from the main operating room and outpatient surgery center at Grady Memorial Hospital who are undergoing elective surgery under general anesthesia, who has received NMB, received neostigmine for NMB reversal, and achieved a TOF count ≥ 3 twitches but not a TOF ratio of 0.9 fifteen minutes after neostigmine was given. Those with a TOF count < 3 twitches will drop out of the study as there are already specified doses of sugammadex for that level of NMB

NCT ID: NCT05632107 Recruiting - Clinical trials for Neuromuscular Blockade

Comparison of an Acceleromyography- and Electromyography-based Neuromuscular Monitor With TOF-Watch ® Monitor

Start date: February 1, 2023
Phase:
Study type: Observational

A quantitative neuromuscular monitoring device is desirable to titrate the depth of neuromuscular block (NMB) during a procedure, and to prevent residual effects after removal of the endotracheal tube. Unfortunately, the most widely used monitoring technique acceleromyography (AMG) typically implies a series of cumbersome installation and calibration procedures that frequently precludes correct use of these devices in clinical practice. Electromyography (EMG) has recently attracted a lot of attention as an alternative strategy to compensate for the deficiency of AMG-based neuromuscular monitors. Nowadays, a new technology that allows for the simultaneous acquisition of EMG and AMG signals is commercially available. Although its reliability has been rapidly accepted in Physical Medicine and Rehabilitation, the use of the technique in neuromuscular monitoring has never been reported. The aim of the present study is to assess the validity of the new device for estimating the neuromuscular block by comparing with TOF Watch®-SX, which is the most widely accepted AMG-based neuromuscular monitor that has been practiced in the clinical arena for decades.